von Willebrand factor: A marker of endothelial dysfunction in vascular disorders?

被引:399
作者
Lip, GYH
Blann, A
机构
[1] Haemostasis, Thromb. Vasc. Biol. U., University Department of Medicine, City Hospital, Birmingham B18 7QH, Dudley Road
关键词
von Willebrand factor (vWf); thrombogenesis; atherogenesis; endothelium;
D O I
10.1016/S0008-6363(97)00039-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The vascular endothelium is involved in the production of many important substances which are involved in cardiovascular pathophysiology. One such substance which is synthesised by, and stored in, endothelial cells is von Willebrand factor (vWf). When released, vWf appears to mediate platelet aggregation and adhesion. Numerous clinical and experimental reports suggest that high vWf levels reflect damage to the endothelium or endothelial dysfunction. The close association between vWf and the processes of thrombus formation (thrombogenesis) or atherogenesis also suggests that high vWf levels may be a useful indirect indicator of atherosclerosis and/or thrombosis. The availability of a useful marker of endothelial dysfunction may have potential clinical value. The measurement of such a marker can perhaps be a non-invasive way of assisting in clinical diagnosis or as an indicator of disease progression. High vWf levels have also been shown to have prognostic value in patients with ischaemic heart disease, peripheral vascular disease and inflammatory vascular disease. However, there is limited information that increased vWf is actually causal in the progression of vascular disease and that measures aimed at reducing vWf levels will be beneficial. In addition, interpretation of raised plasma vWf levels is complicated by the fact that vWf may be an acute phase reactant. Further research is indicated to explore the predictive value of this marker in population studies and, perhaps, therapeutic approaches in (and the value of) modulating vWf levels or function.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 119 条
  • [81] MICROALBUMINURIA AND ENDOTHELIAL DYSFUNCTION IN ESSENTIAL-HYPERTENSION
    PEDRINELLI, R
    GIAMPIETRO, O
    CARMASSI, F
    MELILLO, E
    DELLOMO, G
    CATAPANO, G
    MATTEUCCI, E
    TALARICO, L
    MORALE, M
    DENEGRI, F
    DIBELLO, V
    [J]. LANCET, 1994, 344 (8914) : 14 - 18
  • [82] PENNING CA, 1985, J CLIN LAB IMMUNOL, V17, P125
  • [83] CORRELATION OF CIRCULATING VONWILLEBRAND-FACTOR LEVELS WITH CARDIOVASCULAR HEMODYNAMICS
    PENNY, WF
    WEINSTEIN, M
    SALZMAN, EW
    WARE, JA
    [J]. CIRCULATION, 1991, 83 (05) : 1630 - 1636
  • [84] PHILLIPS MD, 1988, BLOOD, V72, P1898
  • [85] POBER JS, 1988, AM J PATHOL, V133, P426
  • [86] VONWILLEBRAND-FACTOR IS AN ACUTE PHASE REACTANT IN MAN
    POTTINGER, BE
    READ, RC
    PALEOLOG, EM
    HIGGINS, PG
    PEARSON, JD
    [J]. THROMBOSIS RESEARCH, 1989, 53 (04) : 387 - 394
  • [87] HOMOCYSTEINEMIA - ASSOCIATION OF A METABOLIC DISORDER WITH VASCULAR-DISEASE AND THROMBOSIS
    REES, MM
    RODGERS, GM
    [J]. THROMBOSIS RESEARCH, 1993, 71 (05) : 337 - 359
  • [88] LINOLEIC-ACID CONTENT IN ADIPOSE-TISSUE AND CORONARY HEART-DISEASE
    RIEMERSMA, RA
    WOOD, DA
    BUTLER, S
    ELTON, RA
    OLIVER, M
    SALO, M
    NIKKARI, T
    VARTIAINEN, E
    PUSKA, P
    GEY, F
    RUBBA, P
    MANCINI, M
    FIDANZA, F
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1986, 292 (6533): : 1423 - 1427
  • [89] ROSENBAUM J, 1988, CLIN EXP IMMUNOL, V72, P450
  • [90] HEMOPHILIA PROTECTS AGAINST ISCHEMIC-HEART-DISEASE - A STUDY OF RISK-FACTORS
    ROSENDAAL, FR
    BRIET, E
    STIBBE, J
    VANHERPEN, G
    GEVERSLEUVEN, JA
    HOFMAN, A
    VANDENBROUCKE, JP
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (04) : 525 - 530